Genfit S.A. (EPA:GNFT – Get Free Report)’s stock price was down 1.8% during trading on Tuesday . The stock traded as low as €5.37 ($5.90) and last traded at €5.37 ($5.90). Approximately 284,282 shares were traded during mid-day trading, The stock had previously closed at €5.47 ($6.01).
Genfit Stock Down 1.8 %
The company’s fifty day moving average price is €4.67 and its two-hundred day moving average price is €4.17.
Genfit Company Profile
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Read More
- Five stocks we like better than Genfit
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Bank Stocks – Best Bank Stocks to Invest In
- Insider Buying Signals Upside for These 3 Stocks
- Where Do I Find 52-Week Highs and Lows?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
